Baldwin Wealth Partners’s Recursion Pharmaceuticals RXRX Stock Holding History

Baldwin Wealth Partners’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-7,336	Closed	-$73.1K	–	818
2024 Q1	$73.1K	Hold	7,336	–	–	0.01%	310
2023 Q4	$72.3K	Hold	7,336	–	–	0.01%	325
2023 Q3	$56.1K	Buy	7,336 +1,834	+33%	+$18.3K	﹤0.01%	380
2023 Q2	$41.1K	Hold	5,502	–	–	﹤0.01%	436
2023 Q1	$36.7K	Hold	5,502	–	–	﹤0.01%	460
2022 Q4	$42.4K	Hold	5,502	–	–	﹤0.01%	434
2022 Q3	$59K	Buy	5,502 +2,751	+100%	+$27.9K	0.01%	313
2022 Q2	$22K	Buy	+2,751	New	+$18.4K	﹤0.01%	465
2022 Q1	–	Sell	-2,751	Closed	-$47K	–	693
2021 Q4	$47K	Buy	+2,751	New	+$51.8K	﹤0.01%	354

Other funds holding RXRX

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

MIC

Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return

Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baldwin Wealth Partners's RXRX Position: Q2 2024 in Review

Baldwin Wealth Partners sold out of Recursion Pharmaceuticals (RXRX) in Q2 2024, closing a stake of 7,336 shares — an estimated $73.1K sold.

Baldwin Wealth Partners first reported a position in RXRX in Q4 2021 and held it in 9 quarters. The position peaked at $73.1K in Q1 2024. 270 funds tracked by Wall St. Rank hold RXRX as of Q2 2024.

Baldwin Wealth Partners reported no remaining Recursion Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Baldwin Wealth Partners sold 7,336 Recursion Pharmaceuticals shares in Q2 2024, an estimated $73.1K.
Baldwin Wealth Partners first reported a position in Recursion Pharmaceuticals in Q4 2021 and held it in 9 quarters.
Baldwin Wealth Partners's Recursion Pharmaceuticals position peaked at $73.1K in Q1 2024.
270 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2024.

Based on Baldwin Wealth Partners's 13F filing for Q2 2024, filed 12 Jul 2024.